Literature DB >> 22355270

Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.

Hong Wei Yang1, Tae-Min Kim, Sydney S Song, Nihal Shrinath, Richard Park, Michel Kalamarides, Peter J Park, Peter M Black, Rona S Carroll, Mark D Johnson.   

Abstract

Mutations of the NF2 gene on chromosome 22q are thought to initiate tumorigenesis in nearly 50% of meningiomas, and 22q deletion is the earliest and most frequent large-scale chromosomal abnormality observed in these tumors. In aggressive meningiomas, 22q deletions are generally accompanied by the presence of large-scale segmental abnormalities involving other chromosomes, but the reasons for this association are unknown. We find that large-scale chromosomal alterations accumulate during meningioma progression primarily in tumors harboring 22q deletions, suggesting 22q-associated chromosomal instability. Here we show frequent codeletion of the DNA repair and tumor suppressor gene, CHEK2, in combination with NF2 on chromosome 22q in a majority of aggressive meningiomas. In addition, tumor-specific splicing of CHEK2 in meningioma leads to decreased functional Chk2 protein expression. We show that enforced Chk2 knockdown in meningioma cells decreases DNA repair. Furthermore, Chk2 depletion increases centrosome amplification, thereby promoting chromosomal instability. Taken together, these data indicate that alternative splicing and frequent codeletion of CHEK2 and NF2 contribute to the genomic instability and associated development of aggressive biologic behavior in meningiomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22355270      PMCID: PMC3281938          DOI: 10.1593/neo.111574

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  34 in total

1.  Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee.

Authors:  W H Lee
Journal:  Neurosurgery       Date:  1990-09       Impact factor: 4.654

2.  PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.

Authors:  Shutong Yang; Christin Kuo; John E Bisi; Myung K Kim
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

3.  Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.

Authors:  Stéphane Goutagny; Hong Wei Yang; Jessica Zucman-Rossi; Jennifer Chan; Jonathan M Dreyfuss; Peter J Park; Peter M Black; Marco Giovannini; Rona S Carroll; Michel Kalamarides
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

4.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

5.  Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.

Authors:  J Falck; C Lukas; M Protopopova; J Lukas; G Selivanova; J Bartek
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

6.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.

Authors:  N H Chehab; A Malikzay; M Appel; T D Halazonetis
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

7.  Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Ramazan Durmaz; Hamza Müslümanoğlu; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Acta Neurol Belg       Date:  2002-06       Impact factor: 2.396

8.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

9.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Authors:  R H Lekanne Deprez; A B Bianchi; N A Groen; B R Seizinger; A Hagemeijer; E van Drunen; D Bootsma; J W Koper; C J Avezaat; N Kley
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

10.  The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.

Authors:  Maria Castedo; Jean-Luc Perfettini; Thomas Roumier; Kenichi Yakushijin; David Horne; René Medema; Guido Kroemer
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

View more
  15 in total

1.  Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.

Authors:  Karuna Mittal; Angela Ogden; Michelle D Reid; Padmashree C G Rida; Sooryanarayana Varambally; Ritu Aneja
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Chromosome 22q12.1 microdeletions: confirmation of the MN1 gene as a candidate gene for cleft palate.

Authors:  Jeroen Breckpot; Britt-Marie Anderlid; Yasemin Alanay; Moira Blyth; Afane Brahimi; Bénédicte Duban-Bedu; Odile Gozé; Helen Firth; Mustafa Cengiz Yakicier; Greet Hens; Maissa Rayyan; Eric Legius; Joris Robert Vermeesch; Koen Devriendt
Journal:  Eur J Hum Genet       Date:  2015-05-06       Impact factor: 4.246

Review 4.  Mechanisms of genome instability induced by RNA-processing defects.

Authors:  Yujia A Chan; Philip Hieter; Peter C Stirling
Journal:  Trends Genet       Date:  2014-05-01       Impact factor: 11.639

5.  ARID1A and TERT promoter mutations in dedifferentiated meningioma.

Authors:  Malak S Abedalthagafi; Wenya Linda Bi; Parker H Merrill; William J Gibson; Matthew F Rose; Ziming Du; Joshua M Francis; Rose Du; Ian F Dunn; Azra H Ligon; Rameen Beroukhim; Sandro Santagata
Journal:  Cancer Genet       Date:  2015-03-18

6.  MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2.

Authors:  Ya-Zeng Huang; Jun Zhang; Hai-Yu Shao; Jin-Ping Chen; Hong-Ying Zhao
Journal:  Tumour Biol       Date:  2015-03-14

7.  Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.

Authors:  Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

8.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

9.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Authors:  Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

Review 10.  Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Mirna Lechpammer
Journal:  Cancers (Basel)       Date:  2016-07-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.